Literature DB >> 7031389

A brief review of experiences with short-term clinical trials monitored by mouse-foot-pad-inoculation.

C C Shepard.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1981        PMID： 7031389     DOI： 10.5935/0305-7518.19810040

Source DB:  PubMed          Journal:  Lepr Rev        ISSN： 0305-7518            Impact factor:   0.537


× No keyword cloud information.
  10 in total

1.  Novel assay for screening rifamycin B-producing mutants.

Authors:  R M Vohra
Journal:  Appl Environ Microbiol       Date:  1992-01       Impact factor: 4.792

2.  A clinical trial of minocycline in lepromatous leprosy.

Authors:  R H Gelber; K Fukuda; S Byrd; L P Murray; P Siu; M Tsang; T H Rea
Journal:  BMJ       Date:  1992-01-11

3.  The incubation time of relapses after treatment of multibacillary leprosy with rifampicin containing regimens.

Authors:  S R Pattyn; G Groenen; J Bourland; A De Muynck; S Grillone; G Grossetete; J A Husser; L Janssens
Journal:  Eur J Epidemiol       Date:  1988-06       Impact factor: 8.082

4.  The diarylquinoline R207910 is bactericidal against Mycobacterium leprae in mice at low dose and administered intermittently.

Authors:  Robert Gelber; Koen Andries; Rose Maria D Paredes; Cora Evelyn S Andaya; Jasmin Burgos
Journal:  Antimicrob Agents Chemother       Date:  2009-07-13       Impact factor: 5.191

5.  Clinical trial of ofloxacin alone and in combination with dapsone plus clofazimine for treatment of lepromatous leprosy.

Authors:  B Ji; E G Perani; C Petinom; L N'Deli; J H Grosset
Journal:  Antimicrob Agents Chemother       Date:  1994-04       Impact factor: 5.191

Review 6.  Chemotherapy of lepromatous leprosy: recent developments and prospects for the future.

Authors:  R H Gelber
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1994-11       Impact factor: 3.267

7.  Clinical trial of fusidic acid for lepromatous leprosy.

Authors:  S G Franzblau; G P Chan; B G Garcia-Ignacio; V E Chavez; J B Livelo; C L Jimenez; M L Parrilla; R F Calvo; D L Williams; T P Gillis
Journal:  Antimicrob Agents Chemother       Date:  1994-07       Impact factor: 5.191

8.  Powerful bactericidal activity of moxifloxacin in human leprosy.

Authors:  Fe Eleanor F Pardillo; Jasmin Burgos; Tranquilino T Fajardo; Eduardo Dela Cruz; Rodolfo M Abalos; Rose Maria D Paredes; Cora Evelyn S Andaya; Robert H Gelber
Journal:  Antimicrob Agents Chemother       Date:  2008-06-23       Impact factor: 5.191

9.  Clinical trial of sparfloxacin for lepromatous leprosy.

Authors:  G P Chan; B Y Garcia-Ignacio; V E Chavez; J B Livelo; C L Jimenez; M L Parrilla; S G Franzblau
Journal:  Antimicrob Agents Chemother       Date:  1994-01       Impact factor: 5.191

10.  Leprosy therapy, past and present: can we hope to eliminate it?

Authors:  P V S Prasad; P K Kaviarasan
Journal:  Indian J Dermatol       Date:  2010-10       Impact factor: 1.494
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.